EMEA-000876-PIP03-14-M05
Key facts
| Invented name |
Soliris
|
| Active substance |
Eculizumab
|
| Therapeutic area |
Neurology
|
| Decision number |
P/0514/2020
|
| PIP number |
EMEA-000876-PIP03-14-M05
|
| Pharmaceutical form(s) |
Concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of neuromyelitis optica spectrum disorders
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Alexion Europe SAS
E-mail: pip.enquiries.eu@alexion.com
Tel: +33 147100615 |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|